为您找到相关结果约500个

你是不是要搜索 期刊her2阳性乳腺癌新辅助治疗思考 点击跳转

Detection of HER2 overexpression in biliary tract cancers: Comparison of AmoyDx® HER-2 (29D8) assay withventana PATHWAY anti-HER-2/neu (4B5) assay

Pan-HER tyrosine kinase inhibitor pyrotinib enhances radiosensitivity via ERK1/2 pathway in HER2-positive

Antitumor activity of pan-HER inhibitors in HER2-positive gastric cancer

Clinical Activity of Pan-HER Inhibitors Against HER2-Mutant Lung Adenocarcinoma

HER kinase inhibition in patients with HER2-and HER3-mutant cancers

Outcomes related to delayed initiation of anti-HER 2 therapy in pregnant HER2 positive breast cancer

Comparison of HercepTest (TM) mAb pharmDx (Dako Omnis, GE001) with Ventana PATHWAY anti-HER-2/neu (4B5) in breast cancer: correlation with HER2 amplification and HER2 low status

Gold nanoparticles synthesized from Curcuma wenyujin inhibits HER-2/neu transcription in breast cancercells (MDA-MB-231/HER2)

REAL-WORLD DATA: IMPACT OF LOW HER-2 EXPRESSION IN METASTATIC HR+/HER2-BREAST CANCER TREATED WITH PALBOCICLIB

Efficacy of Dual HER-2 and CDK-4/6 Signaling Blockade at Overcoming Primary HER2 Therapy Resistance in

Clinical implications of HER2 mRNA expression and intrinsic subtype in refractory HER2-positive metastaticbreast cancer treated with pan-HER inhibitor, poziotinib

Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer

Association of HER-2/CEP17 Ratio and HER-2 Copy Number With pCR Rate in HER-2-Positive Breast Cancer

From Anti-HER-2 to Anti-HER-2-CAR-T Cells: An Evolutionary Immunotherapy Approach for Gastric Cancer

GDA-501 HER-2 CHIMERIC ANTIGEN RECEPTOR NATURAL KILLER CELLS: DUAL CYTOTOXICITY IN SOLID TUMORS MEDIATEDVIA HER2 AND TRAIL

为您找到相关结果约500个

共500条页码: 1/34页15条/页